todays meeting , page-33

Thanks one for your reports.

Looks like RP has a good handle on a number of issues but I would take him to task on some others.

1. Low Liquidity affecting share price - this is Bs**t. Anyone who wishes to buy can put in a reasonable bid and it would be taken up by a seller. Problem is they are unwilling to put their money up.

2. One of the major reasons I bought into Biota in the first place was the very low number of shares - around 180m at the time. That combined with the exciting science offered a great opportunity for capital gain if management was up to it. The move to NASDAQ and consolidation of shares dramatically reduced the total number of shares plus the exit from the ASX reduced the capacity of Australian shareholders to trade. An unmitigated disaster.

3. A capital raising at the current share price would be a massive hit on existing (mainly long term) shareholders, so pleased to see it is not being canvassed. In fact a share buy back could be beneficial if Biota had more financial reserves - but this capital is required to tide us over until Lani comes to fruition.

4. The Rhinovirus antiviral (Vapendavir?) potential is unlimited - a cure for the "Common Cold" but limited by claims as beneficial in asthma etc. Why would you go chasing viral meningitis when the potential market is so limited

5 Intravenous Relenza (or LANI) has very significant potential in treatment of critically ill influenza patients.Why is it not being explored with enthusiasm? Does Biota have a stake in the GSM I/V Relenza research or will they just take it and run? I note that GSM are in strife in China for bribery and corruption.

6. What are GSM doing to market Relenza to the "best efforts"??

7. Marketing of LANI ( and Relenza) for day to day treatment of seasonal influenza is potentially a huge market. Hasn't been pursued by GSM. Cook indicated at the last Sydney meeting that they were aiming to put Lani onto the seasonal US influenza market to complement Pandemic stockpiling. Note: Pandemic stockpiling is so lumpy that it destroys investor confidence due to unreliable cash flow.

8. What about hepatitis C antivirals?
9. Antimicrobials?


Enough for now

Good luck tomorrow.

Regards
Kangaroo1

PS At one time I had a $65,000 investment in Biota. Fortunately I now have only about $8,000 on the table so I can afford to remain a long term investor with limited downside!!